Wave Life Sciences Ltd. (WVE)
Does Wave Life Sciences (WVE) Have the Potential to Rally 294.66% as Wall Street Analysts Expect?
The consensus price target hints at a 294.7% upside potential for Wave Life Sciences (WVE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wave Life Sciences (WVE) Upgraded to Buy: Here's Why
Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wave Life Sciences: 'Strong Buy' On DMD NDA Filing WVE-N531 And Released AATD Data
Wave Life Sciences Ltd. retains a Strong Buy rating, driven by near-term Accelerated Approval catalysts for WVE-N531 and WVE-006. The company is on track to file an NDA for WVE-N531 in DMD exon 53 skipping in 2026, targeting approval based on dystrophin production and functional testing. Recent phase 1b/2a data for WVE-006 in AATD showed up to 70.5% Z-AAT reduction with multi-dosing, with key FDA feedback and 600 mg multi-dose data expected in mid/late 2026.
Wave Life Sciences Ltd. (WVE) Shareholder/Analyst Call Transcript
Wave Life Sciences Ltd. (WVE) Shareholder/Analyst Call Transcript
Wave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue Estimates
Wave Life Sciences (WVE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.29 per share a year ago.
Wave Life Sciences (WVE) Surges 9.5%: Is This an Indication of Further Gains?
Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Phase I Data from INLIGHT Trial of WVE-007 for Obesity Transcript
Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Phase I Data from INLIGHT Trial of WVE-007 for Obesity Transcript
WVE Posts Interim Data From Phase I Study on WVE-007, Stock Tanks
Wave Life Sciences stock plunges after interim phase I data for WVE-007 showed modest fat reduction at higher dose, despite some sustained benefits.
Wave Life Sciences shares plummet on weight loss therapy update
Wave Life Sciences (NASDAQ:WVE) saw its shares fall more than 52% following the release of six-month Phase 1 data for WVE-007, its investigational INHBE GalNAc-siRNA therapy, despite results showing improvements in body composition and continued safety and tolerability. The Phase 1 INLIGHT trial reported that a single 240 mg dose of WVE-007 produced placebo-adjusted reductions of 14.3% in visceral fat, 5% in total fat, a 2% increase in lean mass, a 3.3% reduction in waist circumference, and a 0.9% reduction in body weight after six months.
WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of “Moderate Buy” by Brokerages
Shares of WAVE Life Sciences Ltd. (NASDAQ: WVE - Get Free Report) have received an average rating of "Moderate Buy" from the fourteen brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and thirteen have given a buy rating to the company. The average 12-month
Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call Transcript
Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call Transcript
Wave Life Sciences Ltd. (WVE) Presents at 44th Annual J.P.
Wave Life Sciences Ltd. (WVE) Presents at 44th Annual J.P.
